Helius Medical Technologies (NASDAQ:HSDT) Issues Quarterly Earnings Results

Helius Medical Technologies (NASDAQ:HSDT) announced its earnings results on Tuesday. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.09), Zacks reports. Helius Medical Technologies had a negative return on equity of 244.82% and a negative net margin of 1,764.74%. The firm had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.10 million.

Helius Medical Technologies Stock Up 5.7 %

NASDAQ:HSDT opened at $0.44 on Wednesday. The firm has a 50 day moving average of $0.56 and a 200 day moving average of $0.60. Helius Medical Technologies has a 52 week low of $0.37 and a 52 week high of $7.19. The stock has a market capitalization of $1.62 million, a price-to-earnings ratio of -0.07 and a beta of 1.62.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.